EYEPOINT INC (EYPT)
Health Care · Ophthalmic pharmaceuticals / retinal disease therapeutics · NASDAQ
EyePoint Pharmaceuticals is a clinical-stage biopharma developing sustained-release treatments for retinal diseases including wet AMD and diabetic macular edema, with the approved product DEXYCU generating minimal revenue.
What EYEPOINT INC does
EyePoint Pharmaceuticals is a biotechnology company focused on developing and commercializing therapeutics for serious eye disorders. The company utilizes its proprietary bioerodible, sustained-release drug delivery technology to treat retinal diseases. Its primary focus is the clinical development of DURAVYU for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Themes: Ophthalmology / eye disease, Wet AMD / age-related macular degeneration, Diabetic macular edema (DME), Clinical-stage biopharmaceutical, Drug delivery, Heavily dependent on clinical and commercial success of lead product candidate DURAVYU, which is still in development; failure to successfully complete clinical trials or achieve regulatory approval could materially harm business., Significant ongoing operating losses and unprofitability; company has accumulated deficit of $1.19 billion and will likely need additional capital; unable to achieve profitability from future operations., Under DOJ investigation; if unable to reach negotiated resolution, DOJ may commence action that could have material adverse effect on business; even if resolved, may require significant resources for compliance including corporate integrity agreement.
Fundamentals
- Price$5.32 as of 2026-08-21 close
- Market cap$459M as of 2026-08-21
- 1-year return-54.1% 2025-08-21 close $11.60 → 2026-08-21 close $5.32
- P/En/a negative earnings
- Net margin-10994.7% as of 2026-08-24
- Gross margin+41.8% as of 2026-08-24
- ROE-135.8% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)-94.6% as of 2026-08-24
- Revenue CAGR (3y)-8.8% SEC XBRL
- Beta1.59 as of 2026-08-24
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How EYPT compares in its sector
- net profit marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- gross marginbottom 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 10% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How EYEPOINT INC looks technically
EYEPOINT INC (EYPT) is trading 62.1% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 62 trading days ago — a "death cross", a bearish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 21 (a reading of 25+ marks a strong trend). Momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 26, in oversold territory (below 30). MACD, a trend-momentum gauge, turned bearish about 3 trading days ago (its momentum flipped negative). It just made a new 20-day low, breaking below its recent trading range. It is 72.2% below its highest point of the past year. Trading volume is running unusually high — about 3.9× its 30-day average, a sign of heightened interest.
Trend
7
| Distance from the 200-day | it is trading 62.1% below its 200-day average, the long-term trend line — a long-term downtrend | -62.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $12.78 | $12.78 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $14.04 | $14.04 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 17 calendar days ago — the swings before that are what the structure reading is measured on | 17 sessions |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 62 trading days ago — a "death cross", a bearish long-term signal | 62 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 21 (a reading of 25+ marks a strong trend) | 21.0 |
Momentum
3
| 14-day RSI | momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 26, in oversold territory (below 30) | 25.5 |
|---|---|---|
| Position in its 14-day range | it is trading right at the bottom of its 14-day range ($4.98 to $14.76) — its "stochastic" reading is 3 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 3.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 3 trading days ago (its momentum flipped negative) | 3 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $19.11 | $19.11 |
|---|---|---|
| From the 52-week high | it is 72.2% below its 52-week high (its highest price of the past year) | -72.2% |
| Above the 52-week low | it is 6.8% above its 52-week low (its lowest price of the past year) | +6.8% |
| Below the 52-week high | it is 72.2% below its highest point of the past year | 72.2% |
| Since a 20-day breakout | it just made a new 20-day low, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day low, breaking below its recent trading range | 1 session |
| All-time high | its highest closing price on record is $350.00 (set on 2005-08-15) | $350.00 |
| Given back of the 52-week move | over the past year its closes ranged ($5.32 to $18.85), and it has recovered essentially none of its fall from last year’s high — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $13.68 to $14.11. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.0% |
| From the all-time high | it is 98.5% below its all-time high | -98.5% |
| Nearest price level | it is trading 30.6% below a resistance level at $6.95 — a price it turned at twice since 2024-12-20, most recently on 2025-04-23. Since 2024-08-21 it has 0 such levels below the current price and 15 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +30.6% |
| All-time low | its lowest closing price on record is $2.19 (set on 2022-12-16) | $2.19 |
| Above the all-time low | it is 142.9% above its all-time low | +142.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 99% of the past ~6 months) | 99th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.41 between its high and its low — about 26.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.41 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $6.43 and $16.97 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $6.43 – $11.70 – $16.97 |
| Typical daily range (% of price) | its price moves about 26.5% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 26.5% |
| Stretch from the 200-day average | it is trading 6.2 daily ranges below its 200-day average price (62.1% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 6.2 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is running unusually high — about 3.9× its 30-day average, a sign of heightened interest | 3.88× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 10.5% since the prior reading | -10.5% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has softened toward "sell" since the prior reading | 0.14 toward sell |
Candlestick patterns
3
| Since a doji | 6 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 6 sessions ago |
|---|---|---|
| Since a hammer | today, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | today |
| Since a bullish engulfing | 5 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 5 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.5% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.5% |
|---|---|---|
| Open gap | it gapped 59.1% below the previous close 2 sessions ago and has not traded back through the level it left behind at 14.75 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -59.0% |
| Gap filled | a 2.4% gap up opened on 2026-08-10 has been "filled" 7 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 7 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 3 sessions in a row, a -63.93% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 3 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 61.6 percentage points (the stock lost 59.2% while the market gained 2.3%) | -61.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 61.5 percentage points (the stock lost 58.4% while the market gained 3.1%) | -61.5% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 76.4 percentage points (the stock lost 65.3% while the market gained 11.1%) | -76.4% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 74.6 percentage points (the stock lost 54.1% while the market gained 20.5%) | -74.6% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: its RSI momentum gauge is oversold (a beaten-down reading), near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 61% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 7.6% of the share price. | -61.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 60% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $13.15 — a volume-weighted average of daily closes over 152 sessions, not a true tick-by-tick VWAP. | -59.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is 39% below the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is under water. That average is $8.75 — a volume-weighted average of daily closes over 11 sessions, not a true tick-by-tick VWAP. | -39.2% |
Price levels it has turned at before
EYPT last closed at $5.32 on 2026-08-21. Since 2024-08-21 it has turned at 0 prices below its last close and 15 above; the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $6.95 | Resistance | 30.6% above the last close | turned there twice · 2024-12-20 to 2025-04-23 |
| $7.60 | Resistance | 42.9% above the last close | turned there three times · 2024-09-10 to 2025-03-12 |
| $9.23 | Resistance | 73.5% above the last close | turned there twice · 2024-10-25 to 2024-12-09 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Oversold (14-day RSI below 30) · Pulled back from the 12-month high · Unusually heavy trading volume · Broke down to a new 20-day low · MACD just crossed bearish (12/26/9) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.36 mean, 1=Strong Buy…5=Strong Sell) — 13 analysts
- Mean price target$36.62 range $8.00 – $68.00; median $37.00
Analyst estimates, as of 2026-08-20. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for EYPT
- Consensus EPS estimate-$0.9252 next reporting period, as of 2026-08-20
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant, ongoing operating losses and dependence on raising additional capital for operations.","Heavy reliance on the successful clinical and commercial development of the lead product candidate, DURAVYU.","Potential for material adverse effects stemming from a U.S. Department of Justice (DOJ) investigation."]
What changed in the latest 10-Q
AI-assisted comparison of EYPT's 10-Q filed 2026-05-07 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Added reference to 'agreement in principle with the U.S. Attorneys' Office for the District of Massachusetts (DOJ) and the Office of the Inspector General of the Department of Health and Human Services' in newer filing (2026-05-07)
- Added 'our expectations regarding our pending litigation against Ocular Therapeutix, Inc.' in newer filing (2026-05-07)
- Added cash position figure of '$222.5 million at March 31, 2026' in newer filing (2026-05-07)
- Removed:
- Removed reference to 'including the potential for DURAVYU to become a blockbuster franchise' from DURAVYU description in newer filing (2026-05-07)
- Removed 'and planned' from 'ongoing and planned clinical trials' for DURAVYU in newer filing (2026-05-07)
- Removed duplicate bullet point about 'expectations regarding the timing and outcome of our ongoing and planned clinical trials for DURAVYU' in newer filing (2026-05-07)
- Removed reference to 'EYP-2301, a TIE-2 agonist, razuprotafib, formulated in Durasert E' product candidate details in newer filing (2026-05-07)
- Removed 'our strategic alliances with other companies' statement in newer filing (2026-05-07)
- Removed reference to 'along with the net proceeds of approximately $162.1 million from our October 2025 equity financing' in cash position statement in newer filing (2026-05-07)
- Removed 'our ability to obtain additional capital in sufficient amounts and on terms acceptable to us, and the consequences of failing to do so' in newer filing (2026-05-07)
- Removed 'our future expenses and capital expenditures' (replaced with 'our expectations regarding our future expenses and capital expenditures') in newer filing (2026-05-07)
- Removed 'the timing and results of the August 2022 subpoena from the U.S. Attorney's Office' specific reference and replaced with general 'agreement in principle' language in newer filing (2026-05-07)
- Removed 'our ongoing discussions with the government regarding a negotiated resolution' in newer filing (2026-05-07)
- Removed 'our ability to manufacture DURAVYU or any other products or product candidates, in sufficient quantities and quality' statement in newer filing (2026-05-07)
- Removed reference to 'Betta Pharmaceuticals Co., Ltd. (Betta)' from collaboration agreements list in newer filing (2026-05-07)
- Removed 'the impact of the federal government shutdown on our business operations' from risk factors in newer filing (2026-05-07)
- Reworded:
- Changed 'US FDA' to 'U.S. Food and Drug Administration (FDA)' for consistency in newer filing (2026-05-07)
- Changed description of DOJ matter from 'August 2022 subpoena' and 'ongoing discussions' to 'agreement in principle' language in newer filing (2026-05-07)
- Changed cash position reference from 'September 30, 2025' to 'March 31, 2026' in newer filing (2026-05-07)
- Changed 'our expectations regarding the warning letter the Company received' to 'our expectations regarding the warning letter we received' in newer filing (2026-05-07)
- Changed 'the effect of legal and regulatory developments' to reference to 'pending litigation against Ocular Therapeutix, Inc.' in newer filing (2026-05-07)
- Changed 'our ability to reach a negotiated resolution with the government regarding the DOJ subpoena that will not have a material impact on our business or financial condition' to 'our ability to enter into a settlement agreement and corporate integrity agreement with the government regarding the DOJ investigation and uncertainties related to the impact such agreements would have on our business, financial condition and results of operations' in newer filing (2026-05-07)
- Changed risk factor about FDA disruptions from 'including due to a reduction in the FDA's workforce and/or inadequate funding for the FDA' to simpler 'disruptions at the FDA' in newer filing (2026-05-07)
- Changed 'the company's clinical development activities, including DURAVYU' to 'our clinical development activities' removing specific product reference in newer filing (2026-05-07)
- Changed 'uncertainties related to the regulatory authorization or approval process, and available development and regulatory pathways for approval of the Company's product candidates' to 'the Company' removed in newer filing (2026-05-07)
- Notes:
- Newer filing text appears truncated at the end ('forward-looki' instead of 'forward-looking'); older filing text also appears truncated ('filings with t' instead of complete phrase)
- Comparison based on Forward-Looking Statements section of MD&A; full MD&A section content beyond this forward-looking statements note is not provided for either filing
Risk Factors
- Added:
- Newer filing (2026-05-07) shows company name changed from 'EYEPOINT PHARMACEUTICALS, INC.' to 'EYEPOINT, INC.'
- Removed:
- Older filing (2025-11-06) contained 'Deferred revenue – noncurrent' line item of $0 at September 30, 2025 and $10,853 thousand at December 31, 2024; this line item is absent from newer filing
- Notes:
- The two filings cover different reporting periods (Q1 2026 vs. Q3 2025 with 9-month comparisons), making direct financial metric comparisons inappropriate for this analysis
- The financial statements are not directly comparable due to different fiscal periods and year-end dates (March 31, 2026 vs. September 30, 2025)
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 2 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 2 sells ($73167) — 1 selling insider
- Last 180 days1 buy ($19724) · 4 sells ($153294) — 1 buying, 1 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-30. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about EYPT's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding EYPT as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 11,526,552
- Reported value $148,577,260
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 5 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
EYPT had 18,015,023 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
EYPT had 20.9% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 12.35 days to cover at the same settlement.
- Reported short interest (shares) 18,015,023
- Short interest (% of shares outstanding) 20.9%
- Prior settlement (shares) 16,425,378
- Reported change 9.68%
- Days to cover (reported) 12.35
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Regeneron (REGN)
- Roche (RHHBY)
- Novartis (NVS)
- AbbVie (ABBV)
- Apellis Pharmaceuticals (APLS)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare EYPT vs…
Frequently asked questions
What does EYEPOINT INC (EYPT) do?
EyePoint Pharmaceuticals is a biotechnology company focused on developing and commercializing therapeutics for serious eye disorders. The company utilizes its proprietary bioerodible, sustained-release drug delivery technology to treat retinal diseases. Its primary focus is the clinical development of DURAVYU for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
What sector is EYEPOINT INC (EYPT) in?
EYEPOINT INC (EYPT) is classified in the Health Care sector. Its industry is Ophthalmic pharmaceuticals / retinal disease therapeutics. It trades on NASDAQ.
Who are EYEPOINT INC's (EYPT) competitors?
Notable peers of EYEPOINT INC (EYPT) include Regeneron, Roche, Novartis, AbbVie and Apellis Pharmaceuticals. This peer set is informational only — not financial advice.
Is EYEPOINT INC (EYPT) overbought or oversold right now?
EYEPOINT INC (EYPT) is currently in oversold territory (its 14-day RSI is 26, below 30) (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on EYPT come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.